| Name | Title | Contact Details |
|---|
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.
Canada’s Global Life Sciences Venture / Partenaire d’affaires en sciences de la vie au Canada #lifesciences #biotech #sante
Minakem is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Osta Biotechnologies Inc. is a Dollard-Des-Ormeaux, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.